Retatrutide-A Game Changer in Obesity Pharmacotherapy
Obesity and type 2 diabetes mellitus (T2DM) are global health crises with significant morbidity and mortality. Retatrutide, a novel triple receptor agonist targeting glucagon-like peptide-1 (GLP-1), Glucose-Dependent Insulinotropic Polypeptide (GI...
Katsi V, Koutsopoulos G, Fragoulis C et al. — Biomolecules
Emerging pharmacotherapies for obesity: A systematic review
The history of antiobesity pharmacotherapies is marked by disappointments, often entangled with societal pressure promoting weight loss and the prevailing conviction that excess body weight signifies a lack of willpower. However, categories of eme...
Kokkorakis M, Chakhtoura M, Rhayem C et al. — Pharmacological reviews
What is the pipeline for future medications for obesity?
Obesity is a chronic disease associated with increased risk of obesity-related complications and mortality. Our better understanding of the weight regulation mechanisms and the role of gut-brain axis on appetite has led to the development of safe ...
Melson E, Ashraf U, Papamargaritis D et al. — International journal of obesity (2005)
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
The development of glucagon-like peptide 1 receptor agonists (GLP-1RA) for type 2 diabetes and obesity was followed by data establishing the cardiorenal benefits of GLP-1RA in select patient populations. In ongoing trials investigators are interro...
Drucker DJ — Diabetes care
Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?
This narrative review highlights the degree to which new antiobesity medications based on gut-derived nutrient-stimulated hormones (incretins) cause loss of lean mass, and the importance of resistance exercise to preserve muscle. Glucagon-like pep...
Locatelli JC, Costa JG, Haynes A et al. — Diabetes care
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
Retatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors. A 48-week phase 2 obesity study demonstrated weight reductions of 22.8% and 24.2% with retatrutide 8 and 12&...
Sanyal AJ, Kaplan LM, Frias JP et al. — Nature medicine
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose-response relationships with respect to side effects, safety, and efficacy for the treatment of obe...
Jastreboff AM, Kaplan LM, Frías JP et al. — The New England journal of medicine
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
According to current consensus guidelines for type 2 diabetes management, bodyweight management is as important as attaining glycaemic targets. Retatrutide, a single peptide with agonist activity at the glucose-dependent insulinotropic polypeptide...
Rosenstock J, Frias J, Jastreboff AM et al. — Lancet (London, England)